Abstract
Accurate preoperative assessment of tumor burden is critical for planning surgical interventions in patients with pseudomyxoma peritonei (PMP). This study evaluated whether five common serum tumor markers—CEA, CA125, CA 19-9, CA 724, and CA 242—correlate with the Peritoneal Cancer Index (PCI), the standard measure of tumor burden. Analyzing 198 patients, researchers found that all five markers were significantly elevated in high-tumor-burden cases (PCI ≥ 20) and moderately correlated with PCI. These findings suggest that preoperative serum markers can serve as valuable non-invasive indicators to aid surgical planning.
Introduction
Pseudomyxoma Peritonei (PMP) is a rare clinical condition characterized by the progressive accumulation of mucinous ascites and tumor implants throughout the peritoneal cavity. The primary treatment strategy involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The success of these procedures often hinges on the preoperative assessment of tumor burden, typically quantified using the Peritoneal Cancer Index (PCI). While imaging techniques like CT and MRI are standard, they can be subjective and sometimes underestimate disease extent. This study investigates the potential of serum tumor markers as objective, accessible proxies for tumor burden.
Methods and Study Population
This retrospective study analyzed data from 198 PMP patients treated at the Aerospace Center Hospital between 2013 and 2021. Patients were categorized into two groups based on their intraoperative PCI: low tumor burden (PCI ≤ 19) and high tumor burden (PCI ≥ 20).
The researchers measured preoperative levels of five tumor markers: carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CA 19-9, CA 724, and CA 242. Statistical analyses, including the Mann-Whitney U test and Spearman correlation, were used to evaluate the relationship between these markers and the PCI.
Key Results
The study revealed a clear distinction in marker levels between the two groups. All five markers were significantly higher in patients with a high tumor burden compared to those with a low burden (p < 0.001 for all comparisons).
Correlation analysis showed that CA 19-9 had the strongest relationship with PCI (r = 0.466), followed by CEA (r = 0.415), CA 724 (r = 0.379), CA 125 (r = 0.372), and CA 242 (r = 0.317). While these correlations are considered moderate, they provide a statistically significant biological signal that reflects the extent of the disease.
Discussion and Clinical Implications
The findings demonstrate that serum tumor markers are biologically linked to the physical extent of PMP. CA 19-9 emerged as the most sensitive marker for reflecting tumor burden in this cohort. Although these blood tests cannot replace the precision of surgical staging or high-quality imaging, they offer a low-cost, non-invasive adjunct for preoperative evaluation.
Integrating these markers into a multi-modal predictive model alongside CT imaging could help clinicians better identify patients who are candidates for radical surgery versus those who might require more conservative debulking. Future research will focus on validating these results in larger, multi-center prospective trials and refining predictive algorithms.
Conclusion
Preoperative serum tumor markers, particularly CA 19-9 and CEA, moderately reflect the tumor burden in PMP patients. Utilizing these markers in clinical practice can contribute to more informed surgical decision-making and improved patient management.
Summary updated